Plozasiran

In patients with persistent chylomicronemia, plozasiran, a small interfering RNA therapy, was associated with lower triglyceride levels and reduced risk for pancreatitis, researchers reported at the European Society of Cardiology Congress.

The FDA has granted breakthrough therapy designation to Arrowhead Pharmaceuticals’ plozasiran, coupled with diet, to decrease triglycerides in patients with familial chylomicronemia syndrome, according to a company release.

In patients with severe hypertriglyceridemia, plozasiran, a novel RNA interference agent, lowered apolipoprotein C-III and triglycerides and improved other lipid parameters, according to the final results of the phase 2b SHASTA-2 trial.

ATLANTA — In this Healio video exclusive, Erica S. Spatz, MD, MHS, discusses research into lipid disorders from the American College of Cardiology Scientific Session, examining studies aimed at reducing high triglycerides.